Study of ALE.C04 in Patients With Head and Neck Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

February 12, 2025

Study Completion Date

February 12, 2025

Conditions
Head and Neck CancerHead and Neck Squamous Cell Carcinoma
Interventions
DRUG

ALE.C04

Q3W

DRUG

Pembrolizumab

200mg Q3W

Trial Locations (22)

3010

Inselspital, University Hospital Bern, Bern

10060

Candiolo cancer Center,FPO IRCCS, Candiolo

20141

Istituto Europeo Di Oncologia S.R.L., Milan

31059

Oncopole Claudius Regaud, Iuct-Oncopole, Toulouse

33075

Centre Hospitalier Universitaire (CHU) de Bordeaux - Hospitalier Saint-Andre, Bordeaux

44718

Gabrail Cancer Center Research, Canton

48201

Karmanos Cancer Institute, Detroit

63110

Washington University School of Medicine, Lake Saint Louis

85234

Banner MD Anderson Cancer Center, Gilbert

90033

University of Southern California USC Norris Comprehensive Cancer Center, Los Angeles

168583

National Cancer Centre Singapore, Singapore

308433

Tan Tock Seng Hospital, Singapore

06510

Yale University Yale Cancer Center, New Haven

02114

Massachusetts General Hospital, Boston

M5G 1Z5

University Health Network, Princess Margaret Cancer Centre, Toronto

Unknown

Institut Gustave Roussy, Villejuif

Prince Of Wales Hospital, Hong Kong

Fondazione Irccs Istituto Nazionale Dei Tumori Di Milano, Milan

MD Anderson Cancer Center, Madrid

Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela

Incliva Biomedical Research Institute - Hospital Clinico Universitario Valencia, Valencia

08035

Vall d'Hebron Institute of Oncology, Barcelona

Sponsors
All Listed Sponsors
lead

Alentis Therapeutics AG

INDUSTRY

NCT06054477 - Study of ALE.C04 in Patients With Head and Neck Cancer | Biotech Hunter | Biotech Hunter